newsfilter
← Latest News
PR Newswire·

Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development

TORONTO, Jan. 31, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE:BRAX) (OTC:BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disor